Toinv

It is disgusting - 

The agm was less than 60 days ago and the timeline on post covid treatment moved from an interim analysis of trial events in 2nd or 3rd qtr 2024 (see slide 25 of AGM) to "Planning for a Phase 2/3 trial of apabetalone in PCC is expected to be completed in 2024, pending all necessary regulatory approval and securing financing" (see p5 of mda dated 8/11/23) which pushes the pcc results out to 2026. 

Also, I am not sure I understand this correctly. Hepalink conversion option of the lower of $.93 and the 5 day average trading price of RVX on the date of conversion. Does that mean that Hepa could convert the debenture to shares at $.07US per share if done next week? 6mil plus accrued interest at 12% would convert to ~ 100,000,000 shares.

If this ever does get to market there will be 500,000,000 or more shares outstanding

Nondilutive financing eh?

Chicagoest